They showed that ESA decreased the peak clinical severity of experimental autoimmune encephalomyelitis in a dose-dependent manner, with a simultaneous marked decrease of TNF and the pro-inflammatory cytokine IL-6 in the spinal cord. This evidence concerns the gene TNF and experimental autoimmune encephalomyelitis.